ArticleCureus2026
Infant-Type Hemispheric Glioma With NTRK Fusion Responds to Larotrectinib.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infant-type hemispheric glioma is a distinct form of high-grade glioma occurring in infancy and early childhood. It arises in the cerebral hemispheres and is characterized by recurrent molecular alterations involving genes such as NTRK, ROS1, MET, and ALK. We present the case of a four-month-old infant with a large solid-cystic parietal-occipital hemispheric mass. Histologic examination revealed a cellular, poorly differentiated tumor with areas of necrosis and prominent desmoplasia. DNA methylation profiling supported classification as infant-type hemispheric glioma, and next-generation sequencing identified a TPM3::NTRK1 fusion. An integrated diagnosis of infant-type hemispheric glioma was made. Following surgical resection, targeted therapy with an NTRK inhibitor was initiated, resulting in a sustained clinical and radiologic response. This case underscores the importance of integrated histologic and molecular evaluation in establishing the diagnosis and guiding management of these tumors, as well as the clinical relevance of identifying targetable alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.